Investors are advised to be aware of clues given by a biotechnology company’s financial reports before they invest in the highly unpredictable sector, experts said at a forum yesterday.
Growth prospects, technical capacity, and capital reserves are the main factors to consider in assessing the viability of investing in a biotechnology company, PricewaterhouseCoopers (PwC) Taiwan deputy chairman Audrey Tseng (曾惠瑾) said.
Growth prospects encompasses the business model of a company, and the terms it has established with its distributors that determine licensing schemes and milestone payments upon regulatory approval and reaching of sales targets, Tseng said
Regarding technical capacity, Tseng said that a new drug development company’s prospects can often been seen in its expenditure.
“We assess the rate of growth of research & development expenditure, and its proportion in relations to operating costs and consolidated revenues,” Tseng said.
A biotechnology firm’s survival depends on its cash reserves, she said.
In the event of a failed clinical trial, a company with ample cash might be able to bide its time and continue its research, while its cash-strapped peer perishes, she said.
“We also calculate the number of years a company might be able to continue operating in the black,” Tseng said, adding that she has found levels of cash reserves in the sector to be adequate.
Companies become defenseless when they have ran out of cash, and might have to turn over their unfinished work at bargain prices as their operations go into the red, she said, adding that a number of new drugs developed by Taiwanese companies are based on compounds acquired from foreign companies.
Tseng said that taxes on stock options remains a tremendous challenge for the sector.
In light of the lower salary for key researchers, companies often grant stock options, she added.
However, taxes are due upon the purchase of the new shares, and the expense adds to financial losses by researchers when the shares of their company swings wildly, she said.
INVENTORY DOUBLED: Key parts have backed up in warehouses, halting notebook production, as Acer’s CEO said that a gradual reopening would not solve the problem PC vendor Acer Inc (宏碁) yesterday said that lockdowns in China to control COVID-19 upended key component supply and disrupted PC production, although chip shortages have been improving. While chip supply constraints largely eased in the first quarter, the company faces uneven supplies of key components due to COVID-19 restrictions in China, Acer chairman and CEO Jason Chen (陳俊聖) told an online news conference. “Semiconductor shortage was the biggest problem in the first half of last year,” Chen said. “Now, we are beset by a supply chain issue caused by China's lockdowns.” With key components unable to be delivered and backing up in
MORE THAN BUZZ: The chip designer said it has received numerous orders from automakers to supply 5G modem chips, as it works to expand beyond smartphones MediaTek Inc (聯發科) yesterday said it would ship the first 5G chips for vehicles to customers in the Asia-Pacific region by the end of the year, as it moves to expand the reach of its 5G chips beyond smartphones. The Hsinchu-based chip designer said it has been developing 5G chips for connected vehicles over the past few years, targeting applications such as telematics and in-vehicle information systems. “We are seeing demand for 5G technology from numerous makers of connected cars, including electric vehicle makers. We have obtained numerous orders from automakers to supply 5G modem chips with highly integrated features,” J.C. Hsu
E Ink Holdings Inc (元太科技) yesterday said it would further expand capacity to cope with robust demand for e-paper displays used in e-readers, e-notes and electronic shelf labels, as the COVID-19 pandemic and rising inflation have not dampened consumer demand. Although rising inflation is weakening companies’ purchasing power, E Ink said that its customers have not scaled down orders for e-paper displays used in e-readers. “Reading is still the most affordable leisure activity that people have,” E Ink CEO Johnson Lee (李政昊) told an online investors’ conference in Taipei. As e-books are less expensive than paper books, “we have so far not seen
Covestro Taiwan Ltd (台灣科思創) yesterday launched a new research and development center that is to specialize in resin synthesis and fiberoptic coating after its parent company, Covestro AG, acquired a resins business from Royal DSM, it said. The German company in September 2020 agreed to buy the resins and functional materials business from Royal DSM for about 1.61 billion euros (US$1.69 billion), corporate data showed. The Dutch company’s local units, such as Covestro Resins (ROA) Ltd (帝昇) and Covestro Resins (Taiwan) Ltd (新力美), are next month to be integrated into Covestro Taiwan Ltd, with their employees continuing resins development, Covestro Taiwan said. The